# Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

> **NCT02938520** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 631 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir (CAB) tablet
- **DRUG:** Rilpivirine (RPV) tablet
- **DRUG:** Cabotegravir - Injectable Suspension (CAB LA)
- **DRUG:** Rilpivirine - Injectable Suspension (RPV LA)
- **DRUG:** ABC/DTG/3TC STR - Tablet
- **DRUG:** DTG Tablet

## Key facts

- **NCT ID:** NCT02938520
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-27
- **Primary completion:** 2018-08-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 631 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938520, "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02938520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*